Long-term outcome of patients with vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis

Long-term outcome of patients with vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis

We present the long-term outcomes of 44 patients who developed cerebral venous sinus thrombosis after vaccination with the adenoviral vector ChAdOx1 nCoV-19 COVID-19 vaccine. Assessment of the Extended Glasgow Outcome Scale was performed within 3–6 months after the initial hospital admissions. Patie...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:npj vaccines 2022-07, Vol.7 (1), p.76-76, Article 76
Hauptverfasser: Kehr, Sarah, Berg, Philipp, Müller, Susanne, Fiedler, Sarah A., Meyer, Britta, Ruppert-Seipp, Gabriele, Witzenhausen, Cornelia, Wolf, Marc E., Henkes, Hans H., Oberle, Doris, Keller-Stanislawski, Brigitte, Funk, Markus B.
Format: Artikel
Sprache:eng
Schlagworte:
692/700/155
692/700/478
Biomedical and Life Sciences
Biomedicine
Brief Communication
Cerebrovascular disease
Clinical outcomes
COVID-19 vaccines
Infectious Diseases
Medical Microbiology
Public Health
Side effects
Thrombocytopenia
Thromboembolism
Thrombosis
Vaccine
Vaccines
Virology
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:We present the long-term outcomes of 44 patients who developed cerebral venous sinus thrombosis after vaccination with the adenoviral vector ChAdOx1 nCoV-19 COVID-19 vaccine. Assessment of the Extended Glasgow Outcome Scale was performed within 3–6 months after the initial hospital admissions. Patient outcomes ranged from good recovery (13 patients, 29.6%) to moderate disability (11 patients, 25.0%) and severe disability or vegetative state (6 patients, 13.6%). Fatal outcomes were reported in 14 patients (31.8%).
ISSN:2059-0105
2059-0105
DOI:10.1038/s41541-022-00491-z